

EUROPEAN CLUSTER
COLLABORATION PLATFORM

European Matchmaking event - Development and production of COVID-19 therapeutics 12 and 13 July 2021

Proceedings Report

Written by the European Cluster Collaboration Platform
July 2021

An initiative of the European Union





EUROPEAN COMMISSION

European Innovation Council and Small and Medium-sized Enterprises Executive Agency (EISMEA)

Department I. Innovation ecosystems, SMP/Entrepreneurship & Consumers

Unit I.02 – SMP/COSME Pillar

Sector I.02.3 – Entrepreneurship and Clusters

Contact: Zoran Stamencic

Email: EISMEA-COSME-ECCP@ec.europa.eu

European Commission

B-1049 Brussels



LEGAL NOTICE

This document has been prepared for the European Commission however it reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein.

More information on the European Union is available on the Internet (<http://www.europa.eu>).

Luxembourg: Publications Office of the European Union, 2021

PDF ISBN 978-92-9460-825-3 doi: 10.2826/521017 EA- 08-21-252-EN-N

© European Union, 2021

The Commission's reuse policy is implemented by Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39, <https://eur-lex.europa.eu/eli/dec/2011/833/oj>).

Unless otherwise noted, the reuse of this document is authorised under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence (<https://creativecommons.org/licenses/by/4.0/>). This means that reuse is allowed, provided appropriate credit is given and any changes are indicated



Contents

Event overview.....	2
Participants	5
Feedback of the event.....	6
Meetings	6
Cooperation opportunities.....	9
Follow-up.....	10
Overall quality of the event	10
Testimonials and recommendations.....	17
Annex 1. Follow-up Survey.....	20
Annex 2. Event's Key Performance Indicators.....	24
Annex 3. List of participating companies.....	25

Tables

Table 1. Agenda of the “European Matchmaking event - Development and production of COVID-19 therapeutics”	3
Table 2. Distribution of approved participants per type	6
Table 3. Distribution of the organisations represented in the event per participant type	7
Table 4. Distribution of approved participants per country of origin and per participant type	2
Table 5. Numbers and proportions of host and guest organisations of meetings implemented online through B2Match.....	6
Table 6. Matrix of the meetings implemented online through B2Match.....	8

Figures

Figure 1. Identification of potential business partners during the meetings.....	9
Figure 2. Potential business partners identified	9
Figure 3. Planned follow-up meetings in the context	10
Figure 4. Overall quality of your matchmaking sessions.....	11
Figure 5. Quality of Preparatory Live Webinar	11
Figure 6. Quality of Technical Webinar: Matchmaking Logistics	12
Figure 7. Quality of the launch of the EU matchmaking event.....	13
Figure 8. Quality of the information provided for the event.....	13
Figure 9. Quality of the overall event agenda.....	14
Figure 10. Quality of the overall organisation.....	14
Figure 11. Quality of the matchmaking platform (B2Match).....	15
Figure 12. Relevance and roles of company representatives.....	15

Event Overview



EUROPEAN CLUSTER
COLLABORATION PLATFORM

Strengthening the European economy through collaboration



Event overview



The European Commission's Task Force for Industrial Scale-up of COVID-19 Vaccines, through the European Cluster Collaboration Platform (ECCP)¹ contract managed by the European Innovation Council and SMEs Executive Agency (EISMEA) and with the support of the European Clusters Alliance (ECA)² and the Council of European BioRegions (CEBR)³ organised the "European Matchmaking event - Development and production of COVID-19 therapeutics". This was a fully virtual event held on July 12th – 13th, 2021.

The technical information about the event can be found in B2Match at: <https://development-production-covid19.b2match.io/>

The European Commission issued a press release on July 12th, 2021 about this event⁴.

The objectives of the event were:

- Support the acceleration of the development and upscale of Covid-19 therapeutics production
- Enhance the participation of EU companies in the Covid-19 therapeutics value chains.
- Speed up connections between therapeutics developers, investors and companies such as EU Contract (Development and) Manufacturing Organisations (CDMOs/CMOs), fill & finish, equipment producers, packaging, storage etc.
- Help in retro-planning strategy for the current and future therapeutics production.

Throughout the application period, the event team received 296 applications to participate in the event. During the matchmaking phase, the participants made over 700 meeting requests, revealing the strong interest in the event.

¹ <https://clustercollaboration.eu/>

² <https://clustersalliance.eu/>

³ <https://www.cebr.net/>

⁴ [Daily News 12 / 07 / 2021 \(europa.eu\)](#)



Agenda:

The event's activities included two preparatory webinars, one opening session and two virtual online matchmaking sessions. The agenda is provided in Table 1.

Table 1. Agenda of the "European Matchmaking event - Development and production of COVID-19 therapeutics"

Time	Activity	Platform
14 th June, 2021 14:00 – 14:30 (CEST)	Preparatory live webinar: 'Matching capacities for COVID-19 therapeutics production' to kick-off registration for the event	Zoom Webinar
30 th June, 2021 10:00 – 10:30 (CEST)	Technical live webinar: Matchmaking Logistics	Zoom Webinar
12 th July, 2021 09:00 – 12:00 (CEST)	Launch of the EU matchmaking event on COVID-19 Therapeutics: Experts' seminar	Zoom Webinar
12 th July, 2021 13:00 – 17:00 (CEST)	Matchmaking meetings	B2Match
13 th July, 2021 09:00 – 17:00 (CEST)	Matchmaking meetings	B2Match

The "Preparatory live webinar: Matching capacities for COVID-19 therapeutics production" was focused on providing an overview about the event's concept, objectives, timeline and initial technical procedures⁵.

The participants that fulfilled the criteria to participate in the event were invited to attend a "Technical live webinar: Matchmaking Logistics". This session informed and helped participants on how to conduct successful online meetings⁶.

Agenda of the "Launch of the EU matchmaking event on COVID-19 Therapeutics – Experts' seminar"

Moderator: Marek Przeor, Member of the Task Force for the Industrial Scale-up of COVID-19 vaccines

- 1) Industrial readiness for the production of COVID-19 Therapeutics in the EU
9:05 – 9:15 Commissioner Breton's keynote remarks on EU industrial partnerships and capacity
9:15 – 9:25 Commissioner Kyriakides' keynote remarks on the EU strategy for COVID-19 therapeutics
- 2) Regulatory process and guidance for evaluation and marketing authorisation
9:25 – 9:50 Executive Director of the European Medicines Agency, Emer Cooke + Q&A
- 3) Public procurement in the area of health
9:50 – 10:15 European Health Public Procurement Alliance + Q&A

⁵ <https://development-production-covid19.b2match.io/agenda?session=91362>

⁶ <https://development-production-covid19.b2match.io/agenda?session=91363>



- Mario Comba – SCR Piemonte (Italy) & EHPPA President
- Paul Wiberg Jørgensen – AMGROS (Denmark) – Head of Supply Chain
- Jean-Michel Descoutures – GIP Resah (France) – Pharmacist

4) Guidelines for therapeutics: views from health professionals

10:15 – 10:40 European Respiratory Society, Prof. Nicolas Roche, Guidelines Director, Pneumologie, Hôpital Cochin, AP-HP.Centre - Université de Paris + Q&A

5) Funding for therapeutics development

10:40 – 11:05 European Investment Bank, Felicitas Riedl, Head of Life Science Division + Q&A

6) Views from the industry

11:05 – 11:30 European Federation of Pharmaceutical Industries and Associations, Magda Chlebus, Executive Director for Science Policy and Regulatory Affairs + Q&A

11:30 – 11:45 Council of European BioRegions, Marc Dechamps, president + Q&A

7) Wrap-up & opening of the matchmaking event

11:55 – 12:00 European Commission, Ulla Engelmann, acting Director Networks & Governance, DG GROW

The “Launch of the EU matchmaking event on COVID-19 Therapeutics: Experts’ seminar” was moderated by Marek Przeor, Member of the EU Task Force for Industrial Scale-up of Covid-19 vaccines and therapeutics Team Leader - Cluster Policy in DG GROW D2 (Industrial Forum, Alliances, Clusters) of Directorate D (Networks & Governance) DG GROW (Internal Market, Industry, Entrepreneurship and SMEs).

The Seminar started with vibrant speeches from Commissioner Breton and Commissioner Kyriakides. They stressed the need to mobilise Europe’s capacity and talent in the fight against COVID-19, noting that even though the majority of Europeans are vaccinated, the virus is still circulating and so people need to be treated. In this sense, they emphasised the requirement to develop treatments that meet all health standards and can be produced within the EU Member States

The European Medicines Agency provided important information about the regulatory process and guidance for evaluation and marketing authorisation of new treatments. They identified that – on a monthly basis – an updated list is published for medicines under evaluation to obtain market authorisation in the EU.

Joint procurement seems to be the way forward, as advocated by the European Health Public Procurement Alliance. In addition, according to the European Respiratory Society, COVID-19 clinical practical guidelines can assist in medical decisions about appropriate healthcare treatments for specific clinical circumstances. In this context, the process of guideline development is very important to help practitioners to protect the health of their patients on a daily basis.

Furthermore, the European Investment Bank emphasised the need of funding to have COVID-19 treatments developed and produced within the EU. Targeted operations supporting the fight against COVID-19 already exist. These operations went through a solid review process before being approved.

The European Federation of Pharmaceutical Industries and Associations, the European Cluster Alliance, and the Council of European BioRegions introduced industry views. They showed the



complexity of the value chain, and the related importance of collaboration, networking and information flow to accelerate the development of safe and effective COVID-19 therapeutics.

Ulla Engelmann, acting Director Networks & Governance, Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs closed the Seminar and provided an overview of the conclusions. She then announced the official opening of the matchmaking sessions.

Attendance

Based on the requirements stated in the event's Call for Expression of Interest, the profiles of 257 participants were activated on the B2Match platform. Over the course of the two online matchmaking sessions, the participants scheduled 219 one-on-one matchmaking meetings through the B2match platform.

Marketplace

Participants were able to list their offer and request items and to search for the suitable business partners by these items through the "Marketplace" function of B2Match. In this context, the participants inserted 101 product opportunities and 23 requests.

Participants

The final list of participants selected on the basis of a Call for Expression of Interest launched was published on the B2Match platform. The event was open to organisations/companies with development and production facilities in the EU Member States and the European Economic Area in the following areas:

Treatment developers working on:

- Antiviral
- Antiviral (monoclonal antibody)
- Immunomodulatory
- Anti-inflammatory
- Biomarkers
- Supportive care
- Other (to be specified)

Clinical Research Organisations offering services such as:

- Clinical trials
- Regulatory support
- Research networks (academia)
- Others (to be specified)

Funding providers:

- Public investors, (EU, National, Regional)
- Corporate funds
- Venture capital
- Other

Manufacturing:

- CMOs / CDMOs – Production of drug substance for biologics and small molecules (chemical)
- Fill and Finish, including device for delivery
- Pharma associations and their members



Supply:

- Raw materials
- Consumables
- Disposables, e.g., single-use bioreactor bags, filters, membranes, flow tips
- Equipment
- Liquid Chromatography systems
- Vials, syringes
- Packaging
- Storage
- Shipment & Distribution
- Other

Public procurers

Representatives of hospitals/health academia

As a result of the selection process, which included the verification of the eligibility criteria, a total of 257 participants (representing 211 different organisations) from 296 applicants were accepted on the B2Match platform. A total of 37 participants were not accepted on B2Match, mainly due to the following reasons: (a) not having development and production facilities in the EU, and/or (b) having registered to the event with a non-corporate e-mail.

Table 2 provides the distribution of approved participants per type.

Table 2. Distribution of approved participants per type

Participant Type	Number of participants
Manufacturing	85
Treatment developers	71
Supply	43
Clinical Research Organisations	23
Representatives of hospitals/health academia	20
Funding providers	8
Public procurers	7

In addition, Table 3 provides information about the distribution of the 211 different organisations represented in the event per participant type.



Table 3. Distribution of the organisations represented in the event per participant type

Participant Type	Number of organisations
Manufacturing	67
Treatment developers	58
Supply	31
Clinical Research Organisations	20
Representatives of hospitals/health academia	20
Funding providers	8
Public procurers	7

Table 3 provides the distribution of the event's approved participants per country of origin and per participant type. This table includes countries outside of the EU since the participants representing an organisation with facilities within an EU country were considered valid for participation in the event.



Table 4. Distribution of approved participants per country of origin and per participant type

Country	Clinical Research Org.	Funding providers	Manufac.	Public procurers	Rep. of hospitals and health	Academia	Supply	Treatment developers	Total
EU Countries									
Austria		2	4	1	2		4	3	16
Belgium	1		4	2			1	7	15
Bulgaria			1					1	2
Czech Republic			1	1			1		3
Cyprus				1					1
Denmark			2				2	2	6
Finland									0
France		1	8		1		5	4	19
Germany	4	1	11		1		10	9	36
Hungary			1					1	2
Greece	1		3				1	2	8



Country	Clinical Research Org.	Funding providers	Manufac.	Public procurers	Rep. of hospitals and health	Academia	Supply	Treatment developers	Total
Ireland	1		2				3	2	8
Italy	3		8		2		4	3	20
Latvia			4						4
Lithuania							1	2	3
Luxembourg		1						1	2
Malta		1	2				2		5
Netherlands	1	1	5		2		2	4	15
Poland			4					3	7
Portugal	1		6		1		3	3	14
Romania			2		1				3
Slovenia					1				1
Slovakia			1					1	2
Spain	10		13	2	8			9	42
Sweden							1	3	4



Country	Clinical Research Org.	Funding providers	Manufac.	Public procurers	Rep. of hospitals and health	Academia	Supply	Treatment developers	Total
Non-EU Countries									
Norway	1		1					1	3
Switzerland							3	2	5
United Kingdom			1					4	5
United States		1	1					4	6
TOTAL	23	8	85	7	20	0	43	71	257

Feedback of the event



EUROPEAN CLUSTER
COLLABORATION PLATFORM

Strengthening the European economy through collaboration



Feedback of the event

The feedback of the event was collected through a follow-up survey (see Annex 1), which was uploaded on EUSurvey and sent to the participants after the end of the matchmaking sessions of the second day of the event via the B2Match e-mail tool.

The follow-up survey was sent on 13th July, 2021 and subsequent reminders were sent thereafter.

Of the 219 meetings accepted, 150 meetings were then held through the B2Match platform. The remaining 69 meetings were either not provided or not implemented using B2Match. The 150 meetings implemented through B2Match included a total of 109 participants.

From the 109 participants that conducted meetings through the B2Match platform, 41 participants answered to the follow-up survey (37%). The responses obtained for each of the follow-up surveys until Thursday, 22nd July, 2021, close of business are analysed below.

Meetings

During the booking phase of the event, participants sent over 700 meeting requests, of which 219 were agreed and scheduled.

Table 5 provides an overview the 150 meetings implemented through B2Match. Each meeting had a host who requested the meeting and a guest who accepted.

Table 5. Numbers and proportions of host and guest organisations of meetings implemented online through B2Match

	Host Participation	% of Host	Guest Participation	% of Guests
Representatives of hospitals/health academia	0	0.0%	8	5.3%
Treatment developers	25	16.7%	55	36.7%
Clinical Research Organisations	31	20.7%	9	6.0%
Funding providers	10	6.7%	12	8.0%
Manufacturing	53	35.3%	55	36.7%
Supply	31	20.7%	11	7.3%
Public procurers	0	0.0%	0	0.0%
Total	150		150	

Furthermore,



Table 6 presents a matrix of the 150 meetings implemented through B2Match



Table 6. Matrix of the meetings implemented online through B2Match

		Guest Participant Type						
		Representatives of hospitals/health academia	Treatment developers	Clinical Research Organisations	Funding providers	Manufacturing	Supply	Public procures
Host Participation Type	Representatives of hospitals/health academia	0	0	0	0	0	0	0
	Treatment developers	2	8	1	11	2	1	0
	Clinical Research Organisations	2	24	2	1	2	0	0
	Funding providers	3	4	3	0	0	0	0
	Manufacturing	1	15	3	0	28	6	0
	Supply	0	4	0	0	23	4	0
	Public procures	0	0	0	0	0	0	0



Cooperation opportunities

According to the results provided through the follow-up survey, 36 participants (87% of the respondents) identified potential business partners during the meetings. Of the respondents, 5 identified that they had not identified business partners (Figure 1)




Figure 1. Identification of potential business partners during the meetings

Regarding the number of potential business partners identified, 33 of the 36 respondents that had stated they identified potential business partners identified an average of almost 2.9 potential partners each. Figure 2 provides a detailed distribution of the number of potential business partners identified.




Figure 2. Potential business partners identified



Follow-up

Within the follow-up survey, 21 respondents (51%) stated they had already planned follow-up meetings (Figure 3).




Figure 3. Planned follow-up meetings in the context

Overall quality of the event

Participants were asked to rate the indicators related to the overall quality of the event through a 0 to 5 score (0 being the lowest quality and 5 the highest quality).

- 0 – out of scope
- 1 – very poor
- 2 – poor
- 3 – good
- 4 – very good
- 5 – excellent

The “out of scope” answers were not included in the calculation of the average since they were provided when participants did not have enough information to access the questions.

Overall quality of your matchmaking sessions

According to the results of the follow-up survey, the overall quality of the matchmaking sessions scored 3.43 points on average. As can be seen through the distribution shown on Figure 4, a total of 19 participants rated the quality of matchmaking sessions as “good”, 11 participants rated it as “very good” and 6 participants rated it as “excellent”.




Figure 4. Overall quality of your matchmaking sessions

Quality of Preparatory Live Webinar:

The quality of the Preparatory Webinar: “Matching capacities for COVID-19 therapeutics production” scored 3.93 points on average. As in the distribution shown on Figure 5, a total of 8 participants rated the quality of this webinar as “good”, 12 participants rated it as “very good”, and 8 rated it as “excellent”. 12 participants rated the quality of the webinar as “out of scope” given these participants did not attend the webinar.




Figure 5. Quality of Preparatory Live Webinar



Quality of Technical Live Webinar:

The quality of the Preparatory Webinar: “Matchmaking Logistics” received an average score of 3.93. Considering the distribution provided on Figure 6, a total of 10 participants rated the quality of this webinar as “good”, 10 participants rated it as “very good”, and 8 participants rated the webinar as “excellent”. Furthermore, 13 participants rated the quality of the technical webinar as “out of scope” given these participants did not attend this webinar.




Figure 6. Quality of Technical Webinar: Matchmaking Logistics

Quality of Launch of the EU matchmaking event on COVID-19 Therapeutics

The quality of the “Launch of the EU matchmaking event on COVID-19 Therapeutics event” scored 3.81 points on average. According to the distribution shown on Figure 7, a total of 10 participants rated the quality of the information provided as “good”, 15 participants rated it as “very good” and 6 participants rated it as “excellent”. Furthermore, 9 participants rated the quality of the launch as “out of scope” given these participants did not attend.




Figure 7. Quality of the launch of the EU matchmaking event

Quality of the information provided for the event

The quality of the information provided for the event scored 3.85 points on average. According to the distribution shown on Figure 8, a total of 15 participants rated the quality of the information provided as “good”, 15 participants rated it as “very good” and 9 participants rated it as “excellent”.




Figure 8. Quality of the information provided for the event

Quality of the overall event agenda

The quality of the overall event agenda received an average score of 3.74. Taking into account the distribution provided on Figure 9, a total of 15 participants rated the quality of the overall event agenda as “good” and 13 participants rated it as “very good”. In addition, 9 participants rated the quality of the agenda as “excellent”.




Figure 9. Quality of the overall event agenda

Quality of the overall organisation

Regarding the quality of the overall organisation, this indicator scored 4.02 points on average. According to the distribution shown on Figure 10, a total of 8 participants rated the quality of the overall organisation as “good”, 20 participants rated it as “very good” and 12 participants rated it as “excellent”.




Figure 10. Quality of the overall organisation



Quality of the matchmaking platform (B2Match)

The quality of the matchmaking platform (B2Match) received an average score of 4.07. As shown on Figure 11, 6 participants rated this indicator as “good”, a total of 20 participants rated it as “very good” and 13 participants rated it as “excellent”.




Figure 11. Quality of the matchmaking platform (B2Match)

Relevance and roles of other company representatives that attended your meetings

Regarding the relevance and roles of other company representatives that attended your meetings, this indicator scored 3.63 points on average. According to the distribution shown on Figure 12, a total of 13 participants rated this indicator as “good”, 14 participants rated it as “very good” and 9 participants rated it as “excellent”.




Figure 12. Relevance and roles of company representatives

Testimonials and recommendations



EUROPEAN CLUSTER
COLLABORATION PLATFORM

Strengthening the European economy through collaboration



Testimonials and recommendations

The participants of the “European Matchmaking event - Development and production of COVID-19 therapeutics” were invited to provide feedback and suggestions about the event through the follow-up survey.

The feedback provided by the participants is summarised below.

Overall organisation and technical performance were good. Another topic for Covid-19-related events would be: how to speed up production of different sorts of vaccines and drugs (after the development of a new vaccine or drug).

ZETA GmbH, Germany

“At the matchmaking we got in touch with a number of treatment developers to discuss a potential concept combining our protein biomarkers to predict a severe course of a COVID-19 disease with an early treatment.”

Sciomics GmbH, Germany

“We managed to get a possible consortium and several possible collaborations.”

“Search for consortiums that are being prepared - new collaborations and services.”

Vector B2B, Portugal

“A great opportunity for meeting new business partners!”

ChemCon GmbH, Germany

“We were able to link to one SME for potential future consortium for European call.”

Ai-biopharm, France

“Several partnership opportunities for proposing new treatment strategies.”

NATURALITY R&D, Spain

“I have identified new potential business partners during the meetings held in the context of the event.”

“My congratulations on the excellent organization and quality of the panel during the expert seminar.”

Laboratorio Reig Jofre, S.A., Spain

“We are a Dutch biotech developing novel antiviral drugs. In addition to potential investor, we also got the chances to talk to SMEs in other EU countries developing antiviral drugs targeting different MoA. This enables us with the opportunities to explore the treatment synergy conducted by the innovations of 2 companies.”

Protinhi Therapeutics, Netherlands

“Connected with relevant parties, achieved objective of follow up meetings with potential future clients, connected with new people across Europe.”



VLE Therapeutics Ltd., Ireland

"Interesting knowledge about therapies and programs developer by Academic partners."

Fujifilm Diosynth Biotechnologies, Denmark

"Keep it as it is."

WPD Pharmaceuticals , INC, Poland

"A very good organised event that enabled some interesting new contacts."

Inflarx GmbH, Germany

Partners for further development of therapies against Covid-19

Consejo Superior de Investigaciones Cientificas (CSIC)

Some participants sent testimonials but they preferred not to disclose the name of their company.

"We have made interesting contacts."

"Potential co-operations were detected, but most of them are at a very early stage of development. Very good organisation"

"Identification of a match for business development."

"I have managed to send our presentation to multiple future prospects meaning that we managed to advertise ourselves. Also, we learned more about matchmaking events."

"We expect that this could be a great opportunity for our partners to create long-term relationships or good collaborations, and we also expect that this could help to be more aware of our activities at a European level."

"Identified opportunities to financially support promising COVID-19 therapeutics."

"Everything was right."

"Identified opportunities to financially support promising COVID-19 therapeutics."

"After the presentation of the experts on Monday 12 July morning, we noted a great synergy between the recommendations and requests made in terms of treatment guidelines (presentation by Prof Roche) and what we are developing at our company."

If the results are positive, which we have no doubt they will be, we will have to consider an accelerated procedure for the registration of the product and the devices. We now know the contact persons to move in this direction."

Annexes



EUROPEAN CLUSTER
COLLABORATION PLATFORM

Strengthening the European economy through collaboration



Annex 1. Follow-up Survey

Follow Up - Survey

“European Matchmaking event - Development and production of COVID-19 therapeutics”

European Matchmaking event - Development and production of COVID-19 therapeutics - Immediate follow-up survey

Fields marked with * are mandatory.



European Matchmaking event - Development and production of COVID-19 therapeutics Immediate follow-up survey

Debriefing questionnaire

Company Profile

* Country (as shown in Event registration):

* Company:

* Contact Person:

Consent

☐ I do not agree that the name and country of my company can be made public



* Please indicate your participant type:

at most 1 choice(s)

- ☐ Representatives of hospitals/health academia
- ☐ Treatment developers
- ☐ Clinical Research Organisations
- ☐ Funding providers
- ☐ Manufacturing
- ☐ Supply
- ☐ Public procurers

Impact of the event in your organisation

Please provide feedback about the following aspects related to the impact of the event:

* Have you identified potential business partners during the meetings held in the context of the event?

at most 1 choice(s)

- ☐ Yes
- ☐ No

If yes, please provide the number of potential partners identified
(please quantify the following aspects related to the impact of the event)

* If yes, have you already planned follow-up meetings?

at most 1 choice(s)

- ☐ Yes
- ☐ No

* The overall quality of your matchmaking sessions

(please score from 0 to 5 (0 being the lowest value and 5 the highest value))

- (0 – out of scope
- 1 – very poor
- 2 – poor
- 3 – good
- 4 – very good
- 5 – excellent)

Only values between 0 and 5 are allowed

Overall implementation of the event



Please score from 0 to 5 (0 being the lowest value and 5 the highest value) the following aspects related to the overall quality of the event:

(0 – out of scope

1 – very poor

2 – poor

3 – good

4 – very good

5 – excellent)

* Quality of Preparatory live webinar

Monday, 14th June, 2021; 14h - 14:30h CEST - 'Matching capacities for COVID19 therapeutics production'

(Please leave blank if not applicable)

Only values between 0 and 5 are allowed

* Quality of Technical live webinar

Wednesday, 30th June, 2021; 10:00 – 10:30 (CEST) - Webinar: Matchmaking Logistics

(Please leave blank if not applicable)

Only values between 0 and 5 are allowed

* Quality of Launch of the EU matchmaking event on COVID19 Therapeutics: Experts seminar

Monday, 12th July, 9:00h - 12:00h (CEST)

(Please leave blank if not applicable)

Only values between 0 and 5 are allowed

* Quality of the information provided for the event

Only values between 0 and 5 are allowed

* Quality of the overall event agenda

Only values between 0 and 5 are allowed

* Quality of the overall organisation

Only values between 0 and 5 are allowed

* Quality of the matchmaking platform (B2match)

Only values between 0 and 5 are allowed



- * Relevance of company delegations that attended the event

Only values between 0 and 5 are allowed

Testimonial

- * Please include a few sentences explaining what outcomes or results you have achieved or expect to achieve thanks to this event. The feedback provided will be highly important to assess the impact of the event and help designing future matchmaking activities. Please note your testimonial may be made public.

- * Please share your suggestions to help improve future matchmaking events.

- * I agree that the information collected in this survey by the European Cluster Collaboration Platform is also shared with European Commission, European Clusters Alliance and Council of European BioRegions, and reproduced in the public proceedings.

at most 1 choice(s)

☐ Yes

☐ No

Data Protection Notice

[Data Protection Notice for the Matchmaking Event - COVID-19 therapeutics EU Survey.pdf](#)



Annex 2. Event's Key Performance Indicators

N°	Performance Indicator	Source	Targets & Objectives	Achieved
IA.1	Total number of participants	Event attendance records	150	257
IA.2	Number of bilateral B2B meetings conducted	Event attendance records	300	150
IA.3	Relevance of company delegations	Post event participant follow-up survey	4 ⁷	3.63
IA.4.a	Have you identified potential business partners in your meetings?	Post event participant follow-up survey	N/A	36 out of 41 responses (87%) responses received stated they had identified partners
IA.4.b	If yes, please give the number	Post event participant follow-up survey	N/A	2.9
	Quality of the preparatory information provided	Post event participant follow-up survey	4 ⁷	3.88 ⁸
IA.5	Overall quality of the event	Post event participant follow-up survey	4 ⁷	3.91 ⁹
IA.6	Testimonials from delegates	Specific contacts with delegate members (from ECA / CEBR), and post-event survey – specific questions to be defined by ECCP	15	25

⁷ Based on the follow-up survey results, with participants' rating on a scale of 0 to 5 (0 being the lowest value, 5 being the highest value)

⁸ Average of the indicators "Quality of Preparatory Webinar: Matching capacities for COVID19 therapeutics production", "Quality of Preparatory Webinar: Matchmaking Logistics", "Quality of Launch of the EU matchmaking event on COVID-19 Therapeutics" and "Quality of the information provided for the event"

⁹ Average of the indicators "Quality of Preparatory Live Webinar: Matching capacities for COVID19 therapeutics production", "Quality of Technical Webinar: Matchmaking Logistics", "Quality of Launch of the EU matchmaking event on COVID-19 Therapeutics" "Quality of the information provided for the event", "Quality of the overall event agenda", "Quality of the overall organisation", and "Quality of the matchmaking platform (B2Match)"



Annex 3. List of participating companies

214 company representatives that took part in the event gave their consent to reveal the name of the companies as participants in the matchmaking event. Companies with several facilities in the same country only appear once. Thus, a total of 186 companies is presented below.

Organization	Country
A&C Bio Buffer Ltd	Ireland
AB SCIENCE	France
Abakusz Gold Ltd.	Hungary
ACD Pharmaceuticals AS	Norway
Advanex Europe Ltd	Czech Republic
Agarose Bead Technologies	Spain
Ai-biopharma	France
Albany Molecular Research Inc. (AMRI)	Italy
Alpine Antiviral	Germany
ANRS Maladies Infectieuses Emergentes	France
APC Ltd	Ireland
Aptar Pharma Injectable	France
AquilonPharma	Belgium
AR Packaging	Sweden
Atriva Therapeutics	Germany
Attgeno	Sweden
Austrian Research Promotion Agency	Austria
Avantor	Belgium
Avantor	Germany
Avantor	Ireland
Avantor	Netherlands
AXON Neuroscience - AXON COVIDAX	Slovakia
Baxter Healthcare	Italy
Bill & Melinda Gates Foundation	United States
BioConnection B.V.	Netherlands
Bioingenium	Spain
Biokeralty Research Institute AIE	Spain
Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.	Italy
Biotest AG	Germany
BKM	Germany
Bonino S.p.A.	Italy
Bormioli Pharma	Italy
CEBINA GmbH	Austria
celares GmbH	Germany
Cenexi	France
Centro de Investigación Biomédica de La Rioja	Spain
Ceva Tiergesundheits Riems GmbH	Germany



Organization	Country
ChemCon GmbH	Germany
Cherubino Limited	Malta
Consejo Superior de Investigaciones Científicas (CSIC)	Spain
Consorti Sanitari de Terrassa/ C3-CST research Group	Spain
Consortium of Health and Social Care of Catalonia	Spain
Curtis Health Caps S.A.	Poland
CVBF	Italy
Cytiva	Switzerland
Cyxone	Sweden
DELPHARM	France
Delta biosciences	Lithuania
DEMO Pharmaceuticals	Greece
DHL Express Austria	Austria
DNALytics	Belgium
Dompè Farmaceutici S.p.A	Italy
ErasmusMC, Dept. Cell Biology	Netherlands
EST Tannroda GmbH	Germany
eTheRNA Immunotherapies NV	Belgium
EU-OPENSREEN ERIC	Germany
Eurofins Genomics Germany GmbH	Germany
European Investment Bank	Luxembourg
Evonik Industries AG	Germany
ExeVir	Belgium
ExeVir Bio	Belgium
Exogenus Therapeutics SA	Portugal
Exvostat (Ireland) Limited	Ireland
Farmaindustria	Spain
Fraunhofer ITEM	Germany
Fresenius Kabi	Germany
Fresenius Kabi Austria GmbH	Austria
Fujifilm Diosynth Biotechnologies	Denmark
Fujifilm Diosynth Biotechnologies	United Kingdom
Fundació Clínic per a la Reserca Biomèdica (FCRB)	Spain
Fundació Sant Joan de Déu//Hospital Sant Joan de Déu	Spain
Gesbor Unipessoal Lda	Portugal
GlaxoSmithKline	Belgium
Grace GmbH	Germany
Grupo Azevedos	Portugal
GSK	United Kingdom
GSK	United States
Haemosan LSS GmbH	Austria
Health & Social Care Consortium of Catalonia	Spain
HOS-Technik GmbH	Austria



Organization	Country
Hovione Farmaciencia	Portugal
Humanigen Europe Limited	Ireland
Humanigen, Inc.	United States
HWI pharma services GmbH	Germany
IDIBAPS	Spain
Immunix AG	Germany
IMPACT	France
Industria Farmaceutica Galenica Senese	Italy
INSTITUTE FOR RESEARCH AND INNOVATION - IRIS	Greece
Insud Pharma	Spain
ISA Pharmaceuticals	Netherlands
Josep Carreras Leukaemia Research Institute	Spain
Laboratorio Reig Jofre, S.A.	Spain
LABORATORIOS ALCALÁ FARMA S.L.	Spain
Laboratórios BASI, S.A.	Portugal
Laboratorios Normon, S.A.	Spain
Leiden University Medical Center	Netherlands
Leitat	Spain
León Research	Spain
LINK Medical Research	Norway
Lykera Biomed	Spain
M.A.R. (Macchine Automatiche Riempitrici) S.p.A.	Italy
Mabion SA	Poland
Malta Enterprise	Malta
Micar Innovation (Micar21)	Bulgaria
MIP Pharma GmbH	Germany
MIP PLASTIC GROUP	France
Mithra Pharmaceuticals	Belgium
Mithra Pharmaceuticals SA	Belgium
MORA SAS	France
Müller + Müller-Joh. GmbH + Co. KG	Germany
Naobios	France
NATURALITY Research & Development SL	Spain
Nature Crete Pharmaceuticals	Greece
Neutroplast	Portugal
Novartis	Belgium
Novartis Europharm Ltd	Switzerland
Novasep Pharma Solutions	France
Novasep Pharma Solutions	United Kingdom
NOVAVAX	United States
Novo Nordisk Pharmatech A/S	Denmark
Olainfarm JSC	Latvia
oncomed manufacturing a.s.	Czech Republic




Organization	Country
OrganoTherapeutics	Luxembourg
Overpharma	Portugal
Pall Corporation	Netherlands
PannonPharma Ltd	Hungary
Pharma Holdings AS	Norway
pharma Mt Ltd	Malta
Pharmacelera	Spain
PharmaMar	Spain
Pharmassist Ltd.	Greece
Pivaris BioScience GmbH	Austria
PLAMECA	Spain
Polisano Pharmaceuticals	Romania
POLITICS MATTERS	Belgium
ProActive	Belgium
Promega GmbH	Germany
Protinhi Therapeutics	Netherlands
PTC Therapeutics	United States
QUASAAR GmbH	Germany
RAFARM	Greece
RECENDT - Research Center for Non-Destructive Testing GmbH	Austria
REGPAK BIOPHARMA CONSULTING	Netherlands
Relief Therapeutics Holding AG	Switzerland
Research Center Pharmaceutical Engineering GmbH	Austria
ROHEALTH-Health and Bioeconomy Cluster	Romania
S.A.L.F. S.p.A. Laboratorio Farmacologico	Italy
Sartorius Stedim Biotech GmbH	Germany
Sartorius Stedim FMT SAS	France
Sciomics GmbH	Germany
SCORE consortium	Netherlands
SEPPIC	France
Sharp, part of UDG Healthcare plc	Belgium
Sidam	Italy
Signia Therapeutics	France
Silicio biotechnology	Lithuania
Sobi	Switzerland
SPODRA SIA	Latvia
State Health Service Organisation	Cyprus
Stemlab SA	Portugal
Steriscience Sp. z o.o.	Poland
Sterling Chemical Malta Limited	Malta
Synairgen	United Kingdom
Synovo GmbH	Germany
Tchaikapharma High Quality Medicines Inc	Bulgaria



Organization	Country
Technology Park Ljubljana - DIH HealthDay.si	Slovenia
Thermo Fisher Scientific	Lithuania
Thermo Fisher Scientific	Netherlands
UCD	Ireland
Unilabs	Portugal
UNION therapeutics	Denmark
Universitat de Lleida-IRBLLEIDA	Spain
University of Graz, Institute of Pharmaceutical Sciences	Austria
University of Santiago de Compostela	Spain
URSAPHARM	Germany
VectorB2B	Portugal
VERRETUBEX INDUSTRIE	France
Vicore Pharma	Sweden
VLE Therapeutics Ltd	Ireland
WPD Pharmaceuticals	Poland
Wytwórnia Surowic i Szczepionek BIOMED Sp. z o.o.	Poland
Zentiva	Italy
Zentiva SA	Romania
ZETA GmbH	Austria
ZETA GmbH	Germany





EUROPEAN CLUSTER
COLLABORATION PLATFORM

Written by the European Cluster Collaboration Platform
July 2021

An initiative of the European Union

